Agenus Inc represents values of innovation, collaboration, and integrity in the biotechnology industry. With a dedication to advancing immune-oncology treatments, Agenus Inc focuses on discovering and developing breakthrough therapies for patients with unmet medical needs. The company's corporate philosophy emphasizes the importance of scientific excellence, ethical practices, and strong partnerships for achieving clinical success. Agenus Inc aims to revolutionize cancer treatment by harnessing the power of the immune system and developing personalized solutions. Through its cutting-edge research and commitment to improving patient outcomes, Agenus Inc remains a leading force in the biotech sector.

Agenus Inc is primarily present in the United States, as it is headquartered in Lexington, Massachusetts. The company operates across various states of the US, including California, New York, and Texas. In addition to its strong presence in the US, Agenus Inc also has a global reach with operations in several countries. These include Germany, the United Kingdom, Italy, Switzerland, and Japan, among others. Agenus Inc has established strategic partnerships and collaborations with organizations worldwide, further expanding its footprint and enhancing its presence in the biotechnology and pharmaceutical sectors.

Agenus Inc has achieved significant milestones throughout its journey. Notably, the company made advancements in immuno-oncology, specializing in the discovery and development of innovative cancer treatments. Key achievements include gaining FDA approvals for its proprietary vaccine, Prophage, in treating glioblastoma multiforme, a deadly brain cancer. Agenus Inc has also formed strategic partnerships with leading biopharmaceutical companies, enabling the development of novel checkpoint inhibitors and personalized cancer immunotherapies. By continuously pushing the boundaries of medical research and forging collaborations in the industry, Agenus Inc remains dedicated to revolutionizing cancer treatment and improving patient outcomes.

Agenus Inc. is a biotechnology company specializing in the discovery and development of immunotherapies. Founded in 1994, the company has a strong history in the field of cancer research and has made significant contributions to the advancement of innovative treatment options. Agenus Inc. is known for its expertise in harnessing the power of the immune system to fight various types of cancer. With a diverse pipeline of potential immunotherapeutic candidates, the company strives to revolutionize cancer treatment and improve patient outcomes. Agenus Inc. continues to be a key player in the biotech industry, constantly pushing the boundaries of medical innovation.

The main competitors of Agenus Inc in the market include companies such as Merck & Co., Inc., Bristol-Myers Squibb Company, and Novartis AG. These companies also operate in the biotechnology sector and compete with Agenus Inc in the development and commercialization of innovative immunotherapies and cancer treatments. Agenus Inc aims to differentiate itself by leveraging its unique proprietary technologies and immunology expertise to stay competitive in this rapidly evolving market.

Agenus Inc is primarily active in the biotechnology industry. With a strong focus on immune oncology, the company develops innovative therapies and vaccines to combat cancer and other diseases. Agenus Inc's cutting-edge research and development initiatives aim to harness the power of the immune system to provide targeted treatment options. Their extensive portfolio includes a diverse range of immunotherapies, such as checkpoint inhibitors, personalized cancer vaccines, and antibody-based therapeutics. By leveraging their expertise in biotechnology, Agenus Inc strives to revolutionize healthcare by delivering novel solutions that have the potential to significantly improve patient outcomes in the fight against various diseases, particularly cancer.

Agenus Inc is a biotechnology company focused on the discovery, development, and commercialization of immune-based therapies for the treatment of cancer and other diseases. Their business model revolves around the development and licensing of innovative therapeutic antibodies, vaccines, and adjuvants, which help enhance the body's immune response to fight against various types of cancers. Agenus Inc aims to leverage its deep understanding of the immune system and advanced technologies to deliver breakthrough treatments with the potential to significantly improve patient outcomes. With its robust pipeline and strategic partnerships, Agenus Inc remains dedicated to advancing novel immunotherapies and revolutionizing the field of oncology.

Poměr Agenus P/E je -0,47.

Koeficient Agenus tržních hodnot je 0,81.

AlleAktien kvalitní skóre pro Agenus je 6/10.

očekávané Agenus obrat je 128,88 mil. USD.

očekávané Agenus zisk je -220,55 mil. USD.

Agenus Inc. is a leading company in the field of precision medicine immunooncology. The company specializes in the identification, development, and marketing of innovative immunotherapies for the treatment of cancer. Agenus has a broad product pipeline that includes both immunotherapeutics and licensed products. The company operates in three main business areas: Discovery and Early Development, Clinical Development, and Commercial. Discovery and Early Development is the area where the company applies its scientific and technical expertise to the discovery and exploration of clinically investigated biologics. Products in this segment include antibodies against CTLA-4 and PD-1/PD-L1, as well as other immuno-oncology targets. Clinical Development is the business area where Agenus uses its clinical expertise to advance drug candidates through clinical trials in phases 1-3. Products in this segment include the immunotherapeutics Prophage, AutoSynVax, IMT-CRL, as well as a pipeline of innovative treatments. Commercial is the business area where the company introduces its products to the market. Agenus has entered into many partnerships and licensing agreements with other pharmaceutical and biotech companies to distribute its products worldwide. The company's flagship product is the CTLA-4 inhibitor, which was the first approved immunotherapy and is used for the treatment of melanoma. In addition, Agenus expects further FDA approvals of its products in 2021/22. Agenus combines immunotherapeutics with other treatment modalities, including surgery, radiation therapy, and chemotherapy, to enhance efficacy and combat side effects in cancer therapy. The company also has a pipeline of novel products in research and development, including stimulants, checkpoint inhibitors, and novel vaccine approaches. This pipeline brings Agenus closer to its goal of exploring and developing new and improved ways to treat cancer. Agenus also has a robust patent portfolio and utilizes its innovative QS-21 technology platform in its product development, which serves to enhance immunogenicity and immune response in vaccines. The company also has partnerships with other companies developing QS-21-licensed products for the treatment of oncological and infectious diseases. Overall, Agenus is a growing company that covers all aspects of biopharmaceuticals, including research, development, clinical trials, and marketing. The company is a pioneer in immunooncology and continues to strive for the development of innovative therapies that will contribute to improving treatment outcomes for cancer patients worldwide.

Agenus vyplácí dividendu ve výši 0 USD rozdělenou do výplat během roku.

Dividenda pro Agenus momentálně nemůže být vypočítána nebo společnost žádnou dividendu nevyplácí.

ISIN společnosti Agenus je US00847G7051.

WKN společnosti Agenus je A1JLKZ.

Ticker společnosti Agenus je AGEN.

Během posledních 12 měsíců vyplatila společnost Agenus dividendu ve výši . To odpovídá dividendovému výnosu přibližně . Pro nadcházejících 12 měsíců se očekává, že Agenus vyplatí dividendu ve výši 0 USD.

Výnos z dividend společnosti Agenus aktuálně činí .

Agenus vyplácí čtvrtletní dividendu. Ta je distribuována v měsících .

Agenus vyplácela v posledních 0 letech každý rok dividendu.

Očekává se, že v následujících 12 měsících budou dividendy ve výši 0 USD. To odpovídá dividendovému výnosu 0 %.

Agenus je přiřazen k sektoru 'Zdraví'.

Aby ses mohl podílet na poslední dividendě Agenus ve výši 0 USD, zaznamenané 25. 8. 2024, měl jsi mít akcii ve svém portfoliu před ex-dnem 25. 8. 2024.

Poslední dividendy byly vyplaceny dne 25. 8. 2024.

V roce 2023 společností Agenus bylo vyplaceno 0 USD ve formě dividend.

Dividendy společnosti Agenus jsou vypláceny v USD.